{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:43:35Z","timestamp":1790898215067,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jhep.2022.04.014","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T23:14:42Z","timestamp":1650928482000},"page":"947-956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Feasibility of hepatitis B elimination in high-income countries with ongoing immigration"],"prefix":"10.1016","volume":"77","author":[{"given":"Feng","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeny","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2128-9133","authenticated-orcid":false,"given":"Beate","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-0052","authenticated-orcid":false,"given":"William W.L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.04.014_bib1","series-title":"Hepatitis B","year":"2020"},{"key":"10.1016\/j.jhep.2022.04.014_bib2","series-title":"Global Health Sector Strategy on Viral Hepatitis 2016\u20132021","year":"2016"},{"key":"10.1016\/j.jhep.2022.04.014_bib3","series-title":"Message from the Minister of Health World Hepatitis Day \u2013 July 28, 2018","year":"2018"},{"key":"10.1016\/j.jhep.2022.04.014_bib4","series-title":"Reducing the health impact of sexually transmitted and blood-borne infections in Canada by 2030: a pan-Canadian STBBI framework for action","year":"2019"},{"issue":"2","key":"10.1016\/j.jhep.2022.04.014_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1503\/cmaj.081112","article-title":"Hepatitis B immunization strategies: timing is everything","volume":"180","author":"Mackie","year":"2009","journal-title":"CMAJ"},{"issue":"43","key":"10.1016\/j.jhep.2022.04.014_bib6","doi-asserted-by":"crossref","first-page":"E1299","DOI":"10.1503\/cmaj.200290","article-title":"Prenatal hepatitis B screening, and hepatitis B burden among children, in Ontario: a descriptive study","volume":"192","author":"Biondi","year":"2020","journal-title":"CMAJ"},{"issue":"8","key":"10.1016\/j.jhep.2022.04.014_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1478-3231.2011.02559.x","article-title":"Cost effectiveness of screening immigrants for hepatitis B","volume":"31","author":"Wong","year":"2011","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.jhep.2022.04.014_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Observatory Collaborators","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/hep.32162","article-title":"The viral hepatitis B care cascade: a population-based comparison of immigrant groups","volume":"75","author":"Yasseen","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhep.2022.04.014_bib11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir vs. placebo to prevent perinatal transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jhep.2022.04.014_bib12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1155\/2012\/506819","article-title":"Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines","volume":"26","author":"Coffin","year":"2012","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2022.04.014_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-019-00852-y","article-title":"Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada","volume":"38","author":"Tian","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 3","key":"10.1016\/j.jhep.2022.04.014_bib14","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1073\/pnas.082080899","article-title":"Agent-based modeling: methods and techniques for simulating human systems","volume":"99","author":"Bonabeau","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jhep.2022.04.014_bib15","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2022.04.014_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3138\/canlivj.2018-0008","article-title":"Management of hepatitis B virus infection: 2018 guidelines from the Canadian association for the study of the liver and association of medical microbiology and infectious disease Canada","volume":"1","author":"Coffin","year":"2018","journal-title":"Can Liver J"},{"issue":"10","key":"10.1016\/j.jhep.2022.04.014_bib17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/hep4.1247","article-title":"Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis","volume":"2","author":"Ford","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.04.014_bib18","series-title":"Encyclopedia of information science and technology","first-page":"7470","author":"Khosrow-Pour","year":"2018"},{"issue":"11","key":"10.1016\/j.jhep.2022.04.014_bib19","first-page":"3","article-title":"Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian health measures survey","volume":"24","author":"Rotermann","year":"2013","journal-title":"Health Rep"},{"key":"10.1016\/j.jhep.2022.04.014_bib20","series-title":"2006 census of population","year":"2019"},{"key":"10.1016\/j.jhep.2022.04.014_bib21","series-title":"Data products, 2016 census","year":"2021"},{"key":"10.1016\/j.jhep.2022.04.014_bib22","series-title":"Hepatitis B infection in Canada","year":"2011"},{"key":"10.1016\/j.jhep.2022.04.014_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13643-019-1126-1","article-title":"Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials","volume":"8","author":"Wong","year":"2019","journal-title":"Syst Rev"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, doubleblind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1016\/j.jhep.2022.04.014_bib26","first-page":"313A","article-title":"Long-term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials","volume":"60","author":"Marcellin","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2022.04.014_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/apt.15741","article-title":"Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase","volume":"52","author":"Lee","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2893.2006.00810.x","article-title":"Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion","volume":"14","author":"Chu","year":"2007","journal-title":"J\u00a0Viral Hepat"},{"issue":"7","key":"10.1016\/j.jhep.2022.04.014_bib30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.7326\/0003-4819-147-7-200710020-00004","article-title":"Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B","volume":"147","author":"Hutton","year":"2007","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jhep.2022.04.014_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0016-5085(86)90919-4","article-title":"Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study","volume":"90","author":"Liaw","year":"1986","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jhep.2022.04.014_bib33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7326\/0003-4819-135-9-200111060-00006","article-title":"Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus","volume":"135","author":"Mcmahon","year":"2001","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jhep.2022.04.014_bib34","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2165\/00019053-200725110-00006","article-title":"Cost effectiveness of entecavir vs. lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B","volume":"25","author":"Veenstra","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.jhep.2022.04.014_bib35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.7326\/0003-4819-142-10-200505170-00007","article-title":"Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis","volume":"142","author":"Kanwal","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.04.014_bib36","series-title":"Risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with or without cirrhosis treated with oral antivirals: results of the nationwide HEPNET. Greece cohort study","author":"Papatheodoridis","year":"2009"},{"issue":"5","key":"10.1016\/j.jhep.2022.04.014_bib37","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/gut.2003.020263","article-title":"Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications","volume":"53","author":"Benvegn\u00f9","year":"2004","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib38","first-page":"77","article-title":"Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jhep.2022.04.014_bib39","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/j.1572-0241.2006.00769.x","article-title":"Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis","volume":"101","author":"Kanwal","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2022.04.014_bib40","first-page":"257","article-title":"Hepatitis B infection and liver cirrhosis: a reappraisal from the Mediterranean area","volume":"24","author":"Crax\u00ec","year":"1987","journal-title":"Ann Ist Super Sanita"},{"issue":"5","key":"10.1016\/j.jhep.2022.04.014_bib41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis","volume":"31","author":"D\u2019Amico","year":"1986","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.jhep.2022.04.014_bib42","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib44","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.510290312","article-title":"Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib45","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.jhep.2022.04.014_bib46","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2036.2008.03691.x","article-title":"Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis","volume":"27","author":"Veenstra","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2022.04.014_bib47","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib48","first-page":"19","article-title":"Long term follow-up of a large cohort of inactive HBsAg (+)\/ HBeAg (-)\/ anti-HBe (+) carriers in Greece","volume":"16","author":"Gigi","year":"2007","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib49","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.9778\/cmajo.20160161","article-title":"Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis","volume":"5","author":"Wong","year":"2017","journal-title":"CMAJ Open"},{"key":"10.1016\/j.jhep.2022.04.014_bib50","unstructured":"Statistics Canada. Table\u00a017100014: estimates of the components of international migration, by age and sex, annual, annually (persons). CANSIM (database). Last updated September 29, 2020. http:\/\/clouddc.chass.utoronto.ca.proxy.lib.uwaterloo.ca\/ds\/cansim\/olap\/displayCube.do?action=browse&a=17100014&lang=. Accessed March 22,\u00a02021."},{"key":"10.1016\/j.jhep.2022.04.014_bib51","series-title":"Estimates of births, by sex, annual","year":"2021"},{"key":"10.1016\/j.jhep.2022.04.014_bib52","series-title":"Crude birth rate, age-specific fertility rates and total fertility rate (live births)","year":"2021"},{"key":"10.1016\/j.jhep.2022.04.014_bib53","series-title":"Population projections for Canada (2018 to 2068), provinces and territories (2018 to 2043): technical report on methodology and assumptions","year":"2020"},{"key":"10.1016\/j.jhep.2022.04.014_bib54","series-title":"Perinatal transmission","year":"2020"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib55","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.vaccine.2010.10.075","article-title":"Economic evaluation of infant and adolescent hepatitis B vaccination in the UK","volume":"29","author":"Siddiqui","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.04.014_bib56","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/jpids\/piu064","article-title":"Prevention of perinatal hepatitis B virus transmission","volume":"3","author":"Nelson","year":"2014","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"10.1016\/j.jhep.2022.04.014_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33833-w","article-title":"Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12876-018-0847-2","article-title":"Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries","volume":"18","author":"Li","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2022.04.014_bib59","series-title":"Immunization Coverage Report for School Pupils in Ontario: 2017\u201318 School Year","year":"2019"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/ijms.2.36","article-title":"Natural history and clinical consequences of hepatitis B virus infection","volume":"2","author":"Pan","year":"2005","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jhep.2022.04.014_bib61","series-title":"Canadian immunization guide","year":"2020"},{"key":"10.1016\/j.jhep.2022.04.014_bib62","series-title":"WHO-UNICEF estimates of HepB3 coverage","year":"2020"},{"key":"10.1016\/j.jhep.2022.04.014_bib63","series-title":"Report on hepatitis B and C in Canada: 2014","year":"2017"},{"key":"10.1016\/j.jhep.2022.04.014_bib64","series-title":"Report on hepatitis B and C in Canada: 2016","year":"2019"},{"key":"10.1016\/j.jhep.2022.04.014_bib65","series-title":"Report on hepatitis B and C in Canada: 2017","year":"2019"},{"key":"10.1016\/j.jhep.2022.04.014_bib66","series-title":"Population estimates, quarterly","year":"2021"},{"issue":"2","key":"10.1016\/j.jhep.2022.04.014_bib67","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1473-3099(09)70021-0","article-title":"Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies","volume":"9","author":"Boily","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2022.04.014_bib68","series-title":"Components of projected population growth, by projection scenario (x 1,000)","year":"2021"},{"issue":"8","key":"10.1016\/j.jhep.2022.04.014_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237525","article-title":"Modelling hepatitis B virus infection and impact of timely birth dose vaccine: a comparison of two simulation models","volume":"15","author":"de Villiers","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jhep.2022.04.014_bib70","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ije\/29.4.744","article-title":"A\u00a0mathematical model of hepatitis B virus transmission and its application for vaccination strategy in China","volume":"29","author":"Zhao","year":"2000","journal-title":"Int J Epidemiol"},{"issue":"12","key":"10.1016\/j.jhep.2022.04.014_bib71","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: a modelling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jhep.2022.04.014_bib72","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/hep.30899","article-title":"Modeling progress toward elimination of hepatitis B in Australia","volume":"71","author":"McCulloch","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2022.04.014_bib73","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/s41467-021-26475-6","article-title":"The impact of the timely birth dose vaccine on the global elimination of hepatitis B","volume":"12","author":"de Villiers","year":"2021","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.04.014_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/liv.13307","article-title":"Novel targets for hepatitis B virus therapy","volume":"37","author":"Testoni","year":"2017","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.jhep.2022.04.014_bib75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","article-title":"New antivirals for the treatment of chronic hepatitis B","volume":"26","author":"Soriano","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.jhep.2022.04.014_bib76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bpg.2017.04.007","article-title":"Treatment of hepatitis B virus with combination therapy\u00a0now and in the future","volume":"31","author":"Emery","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.04.014_bib77","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/liv.13304","article-title":"Future anti-HBV strategies","volume":"37","author":"Gane","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.04.014_bib78","series-title":"Life tables, Canada, provinces and territories","year":"2021"},{"issue":"5","key":"10.1016\/j.jhep.2022.04.014_bib79","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.matcom.2009.12.008","article-title":"Complex agent networks explaining the HIV epidemic among homosexual men in Amsterdam","volume":"80","author":"Mei","year":"2010","journal-title":"Math Comput Simul"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822002495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822002495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:05Z","timestamp":1759175225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822002495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0168827822002495"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.04.014","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of hepatitis B elimination in high-income countries with ongoing immigration","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}